Biosensors and wearable devices are gaining substantial interest.

The global wearable biosensors market is a rapidly expanding industry with increasingly growing potential for applications in healthcare and technological advances. With potential in remote patient monitoring, diagnosis, and detection of disease, biosensors and wearable devices are gaining substantial interest due to their opportunities to offer continuous and reliable physiological information allowing for better support of patient needs. As part of SAE Media Group’s leading series of medical device conferences, this year’s event will be exploring the key drivers and innovations of the wearable medical biosensors landscape with insights into the latest technologies uncovering the therapeutic scope of medical biosensors and the potential of wearable sensors for decentralized diagnostic testing. Furthermore, this year’s conference will look at how industry is overcoming unmet needs including battery technologies and flexibility for wearable sensors. With growing digital application, the 2022 agenda will also assess the potential of artificial intelligence coupled with sensors and understand how industry is managing digital outcomes.


As chairs of SAE Media Group and Medical Design Briefs’ Biosensors for Medical Wearables Conference, we invite you to attend this anticipated event taking place on October 24–25, 2022.

With the digital therapeutics and the medical wearable industry growing exponentially year-on-year, this year’s conference aims to bring you engineering updates in wearable device development, the growing landscape of therapeutic applications, AI opportunities for efficient use of digital outcomes and discussions around the growing industry potential of medical wearable biosensors.

The 2022 conference will bring together expertise from individuals in multiple disciplines in the field of Medical Wearables Biosensors. The two-day, packed agenda will offer a series of presentations, through which you will gain insight into advances in the therapeutic application of medical biosensors, updates in wearable sensors for decentralized clinical testing and panel discussions on the future landscape of medical wearables for scalable remote care. Furthermore, this year’s event will explore the unmet needs for biosensor devices addressing the continuum of care, regulatory updates, and advances in continuous monitoring. With the growing need for efficient and impactful data strategies, industry experts will uncover the latest developments in digital clinical evidence generation and AI-based technology platforms for medical biosensor devices to ensure optimal outputs for healthcare providers and improved patient care.

As chairs of the 2022 conference, we look forward to personally welcoming you to this must-attend event in October.

Yours sincerely,

James Mault,

MD, Founder and CEO, BioIntelliSense, Inc.

Andreas Caduff,

Strategic Advisory Board, Digital Medicine Society (DiMe)


  • Explore the latest in biosensor technologies for wearable medical devices for therapeutics applications

  • Uncover the potential of wearable sensors for decentralized diagnostic testing

  • Delve into the evolving research and technologies to overcome unmet needs of the field including flexible sensors and regulatory updates

  • Assess the growing opportunities and sensor technologies being developed in industry for digital medicine and therapeutics through interactive panel discussions

  • Engage in platforms and opportunities for sensors coupled with AI and understand how industry are managing digital outcomes

CONFERENCE PROGRAM, October 24–25, 2022 (all times EDT)


Together with its customers, the medical technology company is breaking new ground to improve the diagnosis and treatment of diseases. In doing so, Raumedic focuses on polymer-based solutions for medical and pharmaceutical applications, as well as on products for intensive care. Raumedic has a global presence and a headcount of approximately 1,000. In its core markets of Europe and North America, the company manufactures using its own cleanroom production facilities.


Medical-Grade Wearables and Continuous Remote Monitoring from In-Hospital to Home

  • A new generation of medical grade wearable sensors can enable continuous multi-parameter patient monitoring both in-hospital and at-home.

  • With the effortless simplicity of passive continuous monitoring, the asynchronous data streams generated by these wearable devices, combined with scalable exception management algorithms, enable more proactive, efficient, and scalable models of care.

  • These new remote care technology solutions can reduce length of stay, detect negative trends early in their course, and deliver better care to more patients at a fraction of the cost.

James Mault, MD, Founder and CEO, BioIntelliSense, Inc.

James Mault, MD, FACS, is the founder and chief executive officer of BioIntelliSense, a data-as-a-service (DaaS) platform company, delivering breakthrough medical-grade biosensor technology with unique clinical intelligence for scalable remote patient monitoring. Prior to BioIntelliSense, Dr. Mault served as senior vice president and chief medical officer of Qualcomm Life for over five years, where his leadership responsibilities included strategic planning and business development, mergers and acquisitions, new product innovation, clinical program and regulatory oversight, health policy and government affairs, global spokesperson, and public relations. Dr. Mault came to Qualcomm Life through its 2013 acquisition of HealthyCircles, a care coordination and remote patient monitoring platform company founded and led by Dr. Mault in 2009. Prior to starting HealthyCircles, he was the medical director of the Health Solutions Group at Microsoft. Dr. Mault has more than 35 years of experience in senior executive positions in the health IT and medical device industry as well as clinical medicine.


Assessing the Evolving Landscape of Wearable Devices for Monitoring and Remote Diagnostics

  • Growing technologies in wearable monitoring in health and medicine.

  • Analyzing the use of consumer technology for medical applications: the good and bad.

  • Uncovering the biosensor technologies to look out for in the near future

  • The sky’s the limit — how should industry be focusing their R&D for optimal opportunities from sensor technologies?

Andreas Caduff, Strategic Advisory Board, Digital Medicine Society (DiMe)

Andreas Caduff has been a driving force in the development of noninvasive and contextualized physiological monitoring. He was serving as CTO of Solianis where he orchestrated the development of non-invasive glucose monitoring. He then founded Biovotion and served for seven years as CEO, offering a state-of-the-art user-centric, analytics-driven ecosystem, powered by medical wearable technology. Biovotion received several international awards and high-caliber endorsements for its innovations, including an award from the XPrize Foundation. Biovotion was acquired by Biofourmis in 2019. Today he is working at the interface of secured medical technology, physiological monitoring, and data science, toward a more holistic view of health.